Bonesupport Holding Ab · OMXSTO:BONEX
Bonesupport Holding Ab — Q4 2021 Earnings Presentation
17 slides from Bonesupport Holding Ab's earnings presentation, Feb 17, 2022
Slide 1: BONESUPPORT Business update Q4 2021
BONESUPPORT Business update Q4(2021) February 17th, 2022 Emil Billbäck, CEO Håkan Johansson, CFO
Slide 2: Disclaimer
DISCLAIMER This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the “Presentation”), relates to BONESUPPORT HOLDIN
Slide 3: BONESUPPORT – Fourth quarter report 2021
BONESUPPORT – Fourth quarter report 2021 Q4 2021: • Net sales SEK 61.4m, growth: 15% versus Q4 2020, +21% in constant exchange rates • EBIT: SEK -21.8 m (SEK -26.7 m) Full year 2021 • Net sales SEK 212.9 m, growth: 18% versus FY 2020, +23% in constant exchange rates - FY sales growth in 2021 versus
Slide 4: COVID-19 impact on market dynamics
COVID-19 impact on market dynamics • Autumn recovery in surgical volumes was disrupted as the Omicron-variant surged in late Nov/ Dec, again placing the health care systems in a state of postponing non-critical surgical procedures. • CERAMENT sales is correlated to number of surgeries, in turn deter
Slide 5: New all-time-high, despite strong Omicron impact at end of quarter 4
New all-time-high, despite strong Omicron impact at end of quarter 4 LTM Quarterly Sales per Segment 225 US distribution with 40 independent 213 225 distributors (dark blue bar) 205 197 200 200 180 181 173 175 Transition in US 166 165 175 US distribution with Zimmer Biomet (light blue bar) distribut
Slide 6: North America: Strong sales growth with continuously increasing market penetration
North America: Strong sales growth with continuously increasing market penetration Q4 2021 • Sales of SEK 34.8 m, reported growth of 22% over Q4 2020, +31% in constant exchange rates • Regionally high hospitalizations, as result of Omicron-variant, has deferred non-critical procedures After period e
Slide 7: EUROW: Market conditions again constrained as Omicron impacts surgical capacity
EUROW Market conditions again constrained as Omicron break-out impacts surgical capacity and hospital access Q4 2021 • Sales of SEK 26.6 m, a growth of 8% vs Q4 2020, +9% in constant exchange rates • Regionally high levels of COVID hospitalized patients. Highlights • Selected clinics have extended s
Slide 8: Strong radiologic validation of bone remodeling in extended Trauma publication
Strong radiologic validation of bone remodeling in extended Trauma publication Aljawadi A, Naylor T et al. (January 05, 2022) Radiological Analysis of Gentamicin Eluting Synthetic Bone Graft Substitute Used in the Management of Patients With Traumatic Bone Voids. Cureus 14(1): e20969. DOI 10.7759/cu
Slide 9: Financial Review
Financial Review
Slide 10: Q4 2021 net sales SEK 61.4 m
Q4 2021 net sales SEK 61.4 m • A 30 percent growth CER in NA despite influence from the pandemic. 22 percent reported growth • A 9 percent growth CER in EUROW despite influence from the pandemic. 8 percent reported growth 10
Slide 11: Net Sales and Gross Margin by North America and EUROW
North America +22% EUROW +8% (+30% CER) (+9% CER) Net Sales Net Sales Q4-21 Q4-21 North America 2021 2020 EUROW 2021 2020 SEK m Q4-21 Q3-21 Q2-21 Q1-21 Q4-20 SEK m Q4-21 Q3-21 Q2-21 Q1-21 Q4-20 Net Sales 34.8 32.7 29.1 25.1 28.6 Net Sales 26.6 22.2 22.7 19.7 24.5 Gross profit 32.7 30.6 27.1 23.3 27.
Slide 12: A 7.9 MSEK profit improvement before long-term incentive provisions
A 7.9 MSEK profit improvement before long-term incentive provisions Key Figures 2021 2020 SEK m Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Net Sales 61.4 54.9 51.8 44.8 53.2 48.1 36.2 43.4 Gross Margin (%) 89.3 89.0 89.5 88.6 89.8 91.4 86.7 88.7 Operating Loss -21.8 -13.3 -25.9 -19.7 -26.7 -19.2 -23.5 -29.2 Cash at pe
Slide 13: Specific topics impacting expenses in Q4
Specific topics impacting expenses in Q4 Key Figures 2021 2020 SEK m Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Selling expenses (less commissions) 38.5 35.5 33.3 31.2 33.9 32.0 23.0 35.0 Sales Commissions 11.4 10.0 9.3 7.9 8.4 9.2 6.9 7.1 Research and Development expenses 14.4 11.3 15.8 12.3 16.5 11.7 14.0 15.8 Admin
Slide 14: Clear Corporate Strategy Driving Value Creation
Clear Corporate Strategy Driving Value Creation
Slide 15: BONESUPPORT journey ahead - Exciting near term milestones
BONESUPPORT journey ahead - Exciting near term milestones Q3 2022: Potential CERAMENT G launch in the US Q2 2022: Q1 2023: Health Economic model SOLARIO data. European efficacy and bone infection US safety study on 500 patients randomized to SOC or CERAMENT G Feb 17th 2021 2022 2023 2024 2025 Q1 202
Slide 16: Strategic execution and situational adaptation
Strategic execution and situational adaptation • Agile commercial adaptation, navigating through pandemic hurdles • Strengthened commercial set up to benefit from post-pandemic dynamic: − Solid and continuously growing customer base in US ➢ Strategic partnership with OrthoPediatrics ➢ + 2 Regional M
Slide 17: Q&A
Q&A